Market Intelligence, Clinical Progress, and High-Purity Reagents for Short Bowel Syndrome and Gastrointestinal Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GLP2R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLP2R ECD-Fc / Mutant Protein – High purity (>95%), Endotoxin <1EU/ug, HEK293 expressed (native glycosylation). | View GLP2R Products |
| Gene Delivery | GLP2R Promise-ORF / Lentivirus – Full-length ORF for stable cell lines; preserves native GPCR conformation for cAMP, calcium flux, and internalization assays. | View GLP2R Products |
| Benchmark Agonist | Recombinant GLP-2 Analog (Teduglutide sequence) – >95% purity, Endotoxin <1EU/ug, sequence verified. | View GLP2R Products |
| Benchmark Antibody | Anti-GLP2R (recombinant positive control, Teduglutide surrogate) – For binding competition assays. | View GLP2R Products |
| Validator | GLP2R siRNA Set – For knockdown verification and specificity checks. | View GLP2R Products |
| Related Target A | GLP1R – Synergistic pathway for metabolic and gastrointestinal homeostasis; critical for selectivity screening. | View GLP1R Products |
| Related Target B | GCGR – Glucagon receptor family homolog; rigorous counter-screening to ensure specificity. | View GCGR Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Maintenance | Premade Lentivirus for robust HEK293/CHO stable cell line generation. |
| Cross-species (cyno/mouse) Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence verified. |
| Subfamily Counter Screening (GLP1R/GCGR) | Homolog panel proteins strictly verified by mass spec; theoretical MW confirmed. |
| Lack of Controls | Clinical Benchmark Agonists (Teduglutide biosimilars) and Antibodies included with >95% purity. |
| False Positives | Validated siRNA included for specificity checks; endotoxin controlled <1EU/ug. |
Live GLP2R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GLP2R therapeutics is intensifying, with major players shifting focus from daily injections (Teduglutide, Takeda) to next-generation long-acting analogs and oral formulations. First-generation therapies have established the standard of care in Short Bowel Syndrome (SBS), and the next wave targets improved compliance through weekly dosing, expanded indications in Inflammatory Bowel Disease (IBD) and mucosal regeneration, and dual GLP1/GLP2 co-agonists for metabolic-intestinal crossover. Key developers include Zealand Pharma (ZP1840, once-weekly), Ironwood (VectivBio, apraglutide), Hanmi Pharmaceutical (small molecule HM-15136 for IBD), and emerging biotechs exploring oral delivery systems.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-acting Peptide Agonists | Takeda, Zealand Pharma, Ironwood (VectivBio) | Short Bowel Syndrome, Intestinal Failure | Cell-based cAMP & Internalization Assay (need lentivirus stable lines) |
| Fc-Fusion Proteins | Amgen, Novo Nordisk | Inflammatory Bowel Disease | Receptor Activation Assay (native GPCR presentation) |
| Small Molecule Agonists | Hanmi Pharmaceutical, various early biotech | IBD, GI tract repair | Selectivity Assay (counter-screen vs GLP1R/GCGR, mutant vs WT proteins) |
| GLP1/GLP2 Dual Agonists | Emerging peptide engineering biotechs | Metabolic-intestinal crossover | Heterodimer Validation (cross-reactive antibodies, dual cell lines) |
Related Targets for Cross-Selling
- GLP1R – Metabolic regulation and gastrointestinal homeostasis; essential for selectivity screening to avoid off-target glucose effects.
- GCGR – Glucagon receptor family homolog; required family-wide specificity profiling.
- FGFR4 / FGF19 – Downstream effector of GLP-2 signaling; mechanistic validation and combination therapy research.
Key Genetic Variations in GLP2R
Based on UniProt O95838, the following natural variants have been documented:
- rs8072568 (VAR_033967)
- rs17681684 (VAR_033968)
- rs16958918 (VAR_033969)
These variants may impact receptor function and should be considered in drug design and patient stratification.